Trial · NCT01698775
Adverse events272
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 272
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory tract infection | Infections and infestations | Omarigliptin (Phase A) | 4 | 106 | 4 |
| other | Upper respiratory tract infection | Infections and infestations | Placebo to Omarigliptin (Phase A) | 8 | 106 | 9 |
| other | Upper respiratory tract infection | Infections and infestations | Omarigliptin (Phase A) → Omarigliptin (Phase B) | 4 | 106 | 4 |
| other | Upper respiratory tract infection | Infections and infestations | Placebo to Omarigliptin (Phase A) → Glipizide (Phase B) | 12 | 106 | 14 |
| other | Hypoglycaemia | Metabolism and nutrition disorders | Omarigliptin (Phase A) | 21 | 106 | 84 |
| other | Hypoglycaemia | Metabolism and nutrition disorders | Placebo to Omarigliptin (Phase A) | 19 | 106 | 88 |
| other | Hypoglycaemia | Metabolism and nutrition disorders | Omarigliptin (Phase A) → Omarigliptin (Phase B) | 27 | 106 | 138 |
| other | Hypoglycaemia | Metabolism and nutrition disorders | Placebo to Omarigliptin (Phase A) → Glipizide (Phase B) | 25 | 106 | 161 |
| other | Oedema peripheral | General disorders | Omarigliptin (Phase A) | 0 | 106 | 0 |
| other | Oedema peripheral | General disorders | Placebo to Omarigliptin (Phase A) | 2 | 106 | 2 |
| other | Oedema peripheral | General disorders | Omarigliptin (Phase A) → Omarigliptin (Phase B) | 4 | 106 | 4 |
| other | Oedema peripheral | General disorders | Placebo to Omarigliptin (Phase A) → Glipizide (Phase B) | 7 | 106 | 7 |
| other | Nasopharyngitis | Infections and infestations | Omarigliptin (Phase A) | 2 | 106 | 2 |
| other | Nasopharyngitis | Infections and infestations | Placebo to Omarigliptin (Phase A) | 4 | 106 | 5 |
| other | Nasopharyngitis | Infections and infestations | Omarigliptin (Phase A) → Omarigliptin (Phase B) | 3 | 106 | 3 |
| other | Nasopharyngitis | Infections and infestations | Placebo to Omarigliptin (Phase A) → Glipizide (Phase B) | 6 | 106 | 7 |
| other | Urinary tract infection | Infections and infestations | Omarigliptin (Phase A) | 3 | 106 | 3 |
| other | Urinary tract infection | Infections and infestations | Placebo to Omarigliptin (Phase A) | 2 | 106 | 2 |
| other | Urinary tract infection | Infections and infestations | Omarigliptin (Phase A) → Omarigliptin (Phase B) | 7 | 106 | 8 |
| other | Urinary tract infection | Infections and infestations | Placebo to Omarigliptin (Phase A) → Glipizide (Phase B) | 3 | 106 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01698775/events